title: [Sleep disorders associated with treatment with rimonabant].
authors.forename: A P
authors.initials: AP
authors.lastname: Sempere
authors.forename: J C
authors.initials: JC
authors.lastname: Giner-Bernabeu
authors.forename: L
authors.initials: L
authors.lastname: Berenguer-Ruiz
authors.forename: M F
authors.initials: MF
authors.lastname: Selles-Galiana
authors.forename: L
authors.initials: L
authors.lastname: Hernandez-Rubio
authors.forename: M
authors.initials: M
authors.lastname: Lezcano-Rodas
mesh_terms: D000328:Adult; D019440:Anti-Obesity Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009765:Obesity / Q000188:drug therapy; D010880:Piperidines / Q000009:adverse effects* / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors; D000077285:Rimonabant; D012893:Sleep Wake Disorders / Q000139:chemically induced*
chemical_list: D019440:Anti-Obesity Agents; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D000077285:Rimonabant